7 Sep 2020 14:33
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Statement regarding Share Price Movement
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the statement made by BBI Solutions Limited earlier today regarding an order from the UK Government and successful independent evaluations in relation to the AbC-19™ test developed by the UK-RTC. This was released by BBI in error and contained incorrect information. The statement has been withdrawn by BBI and should be disregarded. Any future updates on potential UK Government orders or the outcome of independent evaluations will be disclosed to shareholders once these are concluded.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Edward Whiley (Corporate Finance) | |
Alice Lane (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
ODX.L (ODX)